Kelly Financial Services’s Seres Therapeutics MCRB Stock Holding History

Kelly Financial Services’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-12	Closed	-$174	–	487
2024 Q2	$174	Hold	12	–	–	﹤0.01%	744
2024 Q1	$186	Hold	12	–	–	﹤0.01%	752
2023 Q4	$336	Hold	12	–	–	﹤0.01%	722
2023 Q3	$571	Hold	12	–	–	﹤0.01%	670
2023 Q2	$1.15K	Hold	12	–	–	﹤0.01%	591
2023 Q1	$1.36K	Hold	12	–	–	﹤0.01%	560
2022 Q4	$1.34K	Hold	12	–	–	﹤0.01%	538
2022 Q3	$1.54K	Hold	12	–	–	﹤0.01%	537
2022 Q2	$823	Hold	12	–	–	﹤0.01%	573
2022 Q1	$1.71K	Hold	12	–	–	﹤0.01%	530
2021 Q4	$2K	Hold	12	–	–	﹤0.01%	536
2021 Q3	$1.67K	Sell	12 -274	-96%	-$53.6K	﹤0.01%	532
2021 Q2	$240K	Buy	286 +274	+2,283%	+$116K	0.01%	279
2021 Q1	$4.94K	Hold	12	–	–	﹤0.01%	399
2020 Q4	$5.88K	Buy	12 +7	+140%	+$4.1K	﹤0.01%	350
2020 Q3	$2.83K	Hold	5	–	–	﹤0.01%	399
2020 Q2	$476	Buy	+5	New	+$439	﹤0.01%	532

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Kelly Financial Services's MCRB Position: Q3 2024 in Review

Kelly Financial Services sold out of Seres Therapeutics (MCRB) in Q3 2024, closing a stake of 12 shares — an estimated $174 sold.

Kelly Financial Services first reported a position in MCRB in Q2 2020 and held it in 17 quarters. The position peaked at $240K in Q2 2021. 77 funds tracked by Wall St. Rank hold MCRB as of Q3 2024.

Kelly Financial Services reported no remaining Seres Therapeutics position as of Q3 2024 after selling out during the quarter.
Kelly Financial Services sold 12 Seres Therapeutics shares in Q3 2024, an estimated $174.
Kelly Financial Services first reported a position in Seres Therapeutics in Q2 2020 and held it in 17 quarters.
Kelly Financial Services's Seres Therapeutics position peaked at $240K in Q2 2021.
77 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2024.

Based on Kelly Financial Services's 13F filing for Q3 2024, filed 9 Oct 2024.